Pablo Corral: Is Inflammation Really a Therapeutic Target in Atherosclerosis
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Kevin Jon Williams, published in JIM, adding:
“Anti-inflammatory agents in atherosclerosis – and a need for reform: Extraordinary claims require extraordinary evidence
A provocative and timely Perspective by Kevin Jon Williams challenging the inflammatory hypothesis of atherosclerosis.
- ZEUS adds another null result: targeting inflammation did not translate into fewer cardiovascular events (HR approximately 0.99).
- Williams highlights a much broader issue: more than 50 clinical trials of anti-inflammatory strategies in atherosclerosis over decades have produced a remarkably disappointing clinical track record.
- His challenge to the field is uncomfortable but important: should inflammation continue to be considered a definitive therapeutic target in atherosclerosis when repeated clinical testing has failed to deliver consistent benefit?
- In sharp contrast, lowering cholesterol-rich ApoB-containing lipoproteins rests on extensive and reproducible evidence targeting the proven causal agents of atherosclerosis.
As evidence accumulates, are we witnessing regression to the mean – or regression to the truth?
Inflammation may be part of atherosclerosis – but being part of the disease does not make it a proven therapeutic target.”
Title: Anti-inflammatory agents in atherosclerosis – and a need for reform: Extraordinary claims require extraordinary evidence
Authors: Kevin Jon Williams
Other posts featuring Pablo Corral on Hemostasis Today.
-
Sep 29, 2026, 12:02Hajra Malik: Bridging Language Gaps in Hematology With AI
-
Sep 29, 2026, 11:57Joan Montaner: Can Blood Test Identify Intracerebral Hemorrhage Within Minutes?
-
Sep 29, 2026, 11:43From Years Without Answers to Life With Hemophilia Care – WFH
-
Sep 29, 2026, 11:32Sara Al Dallal: Transforming Hemophilia Care Across the Gulf
-
Sep 29, 2026, 11:21Richard Davis: Rapid Rescue in Massive Pulmonary Embolism
-
Sep 29, 2026, 11:14Nissan Brown: Every Step Counts for the Hemophilia Community
-
Sep 29, 2026, 11:03Zain Khalpey: SINGLE AF Adds New Evidence to the Anticoagulation Debate
-
Sep 29, 2026, 10:54How Does Haemophilia Affect Motor Development in Infants? – EAHAD
-
Sep 29, 2026, 10:49Alison Davey: The Vital Role of Community Support in Bleeding Disorders